Sommario

• • ·The real worth of cancer drugs

    Pagina :1537

     
• • ·Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma

    Pagina :1538-1539

    Giuseppe Procopio, Federico Nichetti, Elena Verzoni

     
• • ·The quest for efficient trial designs in precision oncology

    Pagina :1539-1541

    Martin Schuler

     
• • ·Internal mammary node irradiation in breast cancer: does benefit outweigh risk?

    Pagina :1541-1543

    Charlotte E Coles, Joanne S Haviland, Anna M Kirby

    
• • ·Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer

    Pagina :1543-1545

    Giuseppe Curigliano, Gabriella Pravettoni

     
• • ·Duration of adjuvant treatment for patients with stage III colon cancer

    Pagina :1545-1547

    Miriam Koopman, Cornelis J A Punt

     
• • ·BELLINI: a renaissance for an era of precision therapy in multiple myeloma

    Pagina :1547-1549

    Irene Ghobrial

     
• • ·Landmark studies of therapeutic vaccination in cervical and ovarian cancers

    Pagina :1549-1550

    Peter G Rose, Haider Mahdi

     
• • ·Strengthening the global nursing workforce for childhood cancer

    Pagina :1550-1552

    Courtney E Sullivan, Julia Challinor, Pernilla Pergert, Glenn Mbah Afungchwi, Julia Downing, Lisa Morrissey, Melissa A Adde, Rehana Punjwani, André Ilbawi, Rachel Hollis

     
• • ·Time to resume active recommendation of the HPV vaccine in Japan

    Pagina :1552-1553

    Yusuke Tanaka

     
• • ·Deep-learning natural language processing for oncological applications

    Pagina :1553-1556

    Vera Sorin, Yiftach Barash, Eli Konen, Eyal Klang

     
• • ·COVID-19 in patients with cancer

    Pagina :e539

    Carmen Smotherman, Daniel Norez, Rebecca Austin-Datta, Lusine Yaghjyan

    
• • ·Treatments for newly diagnosed multiple myeloma: when endurance is interrupted

    Pagina :e540

    Ola Landgren, David Siegel, Dickran Kazandjian, Luciano Costa, Andrzej Jakubowiak

    
• • ·Treatments for newly diagnosed multiple myeloma: when endurance is interrupted – Authors’ reply

    Pagina :e541

    Shaji K Kumar, Susanna J Jacobus, S Vincent Rajkumar

    
• • ·Drug repurposing in oncology

    Pagina :e542

    Gauthier Bouche, Craig Gedye, Lydie Meheus, Pan Pantziarka

    
• • ·Drug repurposing in oncology

    Pagina :e543

    Maria Frantzi, Agnieszka Latosinska, Marika Mokou, Harald Mischak, Antonia Vlahou

    
• • ·Drug repurposing in oncology – Authors’ reply

    Pagina :e544

    Audrey A Tran, Vinay Prasad

    
• • ·Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer

    Pagina :e545

    Nobuyuki Horita, Hao Chen, Kaneko Takeshi

    
• • ·Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer – Authors’ reply

    Pagina :e546

    Christos Chouaid, Isabelle Monnet, Nathalie Baize

    
• • ·Shifting from targeted therapies to personalised treatment in chordoma

    Pagina :e547

    Quintino Giorgio D’Alessandris, Giuseppe Maria Della Pepa, Martina Offi, Roberto Pallini, Alessandro Olivi

    
• • ·Shifting from targeted therapies to personalised treatment in chordoma – Authors’ reply

    Pagina :e548

    Qi Jia, Su Chen, Chao Liu, Cheng Yang, Jianru Xiao

    
• • ·Enabling hope

    Pagina :e549

    Edward Christopher Dee, William Greig Mitchell, Anthony V D’Amico

    
• • ·The future of liquid biopsy

    Pagina :e550

    Dhruva Biswas, Jane Ganeshalingam, Jonathan C M Wan

     
• • ·Tumour mutational burden in treatment-resistant tumours

    Pagina :e551

    Wei Nie, Jie Qian, Bo Zhang, Hua Zhong, Baohui Han

    
• • ·Tumour mutational burden in treatment-resistant tumours – Authors’ reply

    Pagina :e552

    Aurelien Marabelle, Fan Jin, Kevin Norwood, Deepti Aurora-Garg

    
• • ·Correction to Lancet Oncol 2020; 21: 645–54

    Pagina :e553

    
• • ·Correction to Lancet Oncol 2020; 21: 1563–73

    Pagina :e553

    
• • ·Correction to Lancet Oncol 2020; 21: 1443–54

    Pagina :e553

    
• • ·Correction to Lancet Oncol 2020; 21: e305–16

    Pagina :e553

    
• • ·Correction to Lancet Oncol 2020; 21: e519–27

    Pagina :e553

    
• • ·ASTRO 2020 virtual meeting

    Pagina :1557

    Katherine Gourd

    Mappa Mappa  
• • ·EU4Health budget cut threatens Europe’s Beating Cancer Plan

    Pagina :1558

    Elizabeth Gourd

     
• • ·Lung cancer control in the UK hit badly by COVID-19 pandemic

    Pagina :1559

    Elizabeth Gourd

     
• • ·No-visitor policies cause anxiety and distress for patients with cancer

    Pagina :e554

    Roxanne Nelson

     
• • ·Groesbeck Parham

    Pagina :1560

    Catherine Lucas

     
• • ·A possible case of palaeopathology of leukaemia from Late Antique southern Italy

    Pagina :1561-1562

    Giorgia Tulumello, Marisa Falduto, Ivana Grazia Verboso, Alessara Genga, Tiziana Siciliano, Giovanni Mastronuzzi, Giulia Riccomi

     
• • ·Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

    Pagina :1563-1573

    Thomas Powles, Elizabeth R Plimack, Denis Soulières, Tom Waddell, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor Vynnychenko, Sergio J Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L Rhoda Molife, Michael B Atkins, Brian I Rini

    Riassunto Riassunto Mappa Mappa   
• • ·Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Pagina :1574-1588

    Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt, DANUBE study investigators, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suarez, Hans Westgeest, Yves Fradet, Aude Flechon, Yen-Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez-Valderrama, Susanna Cheng, Stephen Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala Sridhar, Giorgio Vittorio Scagliotti, Jens Voortman, Boris Alekseev, Anna Alyasova, Boris Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, Jose Angel Arranz, Djura Piersma, Sang Joon Shin, Oleg Karyakin, Ignacio Delgado, Jose Luis Gonzalez, See-Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, Monserrat Domenech, Yen-Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, Vasileios Georgoulias, Sasja Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott Tagawa, Pawel Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli, Rosa Tambaro, Yasuhiro Hashimoto, Alexander Nosov, Albert Font, Alejo M. Rodriguez-Vida, Robert Jones, Naveen Vasudev, Sandhya Srinivas, Jingsong Zhang, Thierry Gil, Daygen Finch, Marc-Oliver Grimm, Yu-Li Su, Simon Chowdhury, Christopher Hocking, Eugen Plas, Scott North, Niels Viggo Jensen, Christine Theodore, Florian Imkamp, Avivit Peer, Takashi Kobayashi, Hideki Sakai, Naoto Sassa, Kazuhiro Yoshimura, Maureen Aarts, Ana Ferreira Castro, Marlen Topuzov, Juan Francisco Rodriguez, Federico Jose Vazquez, Yu-Chieh Tsai, Simon Crabb, Syed Hussain, Johanna Bendell, Marine Gross-Goupil, Gravis Gwenaelle, Raanan Berger, Galina Statsenko, Linda Evans, Alexandra Drakaki, Bradley Somer, Ian Davis, James Lynam, Giuliano Borges, Aldo Dettino, André P. Fay, Graziella Martins, Luis Eduardo Zucca, Mads Agerbaek, Haralambos Kalofonos, Eli Rosenbaum, Hideki Enokida, Hiroaki Kikukawa, Kazuo Nishimura, Satoshi Tamada, Motohide Uemura, Yamil Lopez, Jourik Gietema, Marcin Slojewski, Isabel Fernandes, Alexey Smolin, Danish Mazhar, Arash Rezazadeh Kalebasty, Bradley Carthon, Wolfgang Loidl, Fabio Franke, Gustavo Girotto, Nimira Alimohamed, Robyn Macfarlane, Helle Pappot, Guenter Niegisch, Dimitrios Mavroudis, Avishay Sella, Camillo Porta, Shin Ebara, Motonobu Nakamura, Wataru Obara, Norihiko Okuno, Nobuo Shinohara, Mikio Sugimoto, Akitaka Suzuki, Noriaki Tokuda, Hiroji Uemura, Akito Yamaguchi, Francisco Ramirez, Pawel Rozanowski, Pawel Wiechno, Bhumsuk Keam, Nikolay Kislov, Denis Plaksin, Irfan Cicin, Satish Kumar, Matthew D. Galsky, Daniel P. Petrylak, Joseph Rosales, Ulka Vaishampayan, Stephane Culine, Christos Papandreou, Taketoshi Nara, Mustafa Erman, Laurence Kreiger, Juliana Janoski, Diogo Rosa, Mariana Siqueira, Christina Canil, Lisa Sengelov, Jean-Marc Tourani, Gaku Arai, Katsuyoshi Hashine, Mutsushi Kawakita, Noboru Nakaigawa, Hayahito Nomi, Hiroaki Shiina, Hiroyoshi Suzuki, Junji Yonese, Roberto Kuri, Eleazar Macedo, Samuel Rivera, Alberto Villalobos Prieto, Anna Polakiewicz-Gilowska, Renata Zaucha, Fabio Lopes, Roman Ponomarev, Mark Pomerantz, Shahrokh Shariat, Cynthia Luk, Krzysztof Lesniewski-Kmak

    Riassunto Riassunto Mappa Mappa   
• • ·Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

    Pagina :1589-1601

    Mary W Redman, Vassiliki A Papadimitrakopoulou, Katherine Minichiello, Fred R Hirsch, Philip C Mack, Lawrence H Schwartz, Everett Vokes, Suresh Ramalingam, Natasha Leighl, Jeff Bradley, Jieling Miao, James Moon, Louise Highleyman, Crystal Miwa, Michael L LeBlanc, Shakun Malik, Vincent A Miller, Ellen V Sigal, Stacey Adam, David Wholley, Caroline Sigman, Beverly Smolich, Charles D Blanke, Karen Kelly, David R Gandara, Roy S Herbst

    Riassunto Riassunto Mappa Mappa   
• • ·Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

    Pagina :1602-1610

    Philip M Poortmans, Caroline Weltens, Catherine Fortpied, Carine Kirkove, Karine Peignaux-Casasnovas, Volker Budach, Femke van der Leij, Ernest Vonk, Nicola Weidner, Sofia Rivera, Geertjan van Tienhoven, Alain Fourquet, Georges Noel, Mariacarla Valli, Matthias Guckenberger, Eveline Koiter, Severine Racadot, Roxolyana Abdah-Bortnyak, Erik F Van Limbergen, Antoine Engelen, Peter De Brouwer, Henk Struikmans, Harry Bartelink, European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups

    Riassunto Riassunto Mappa Mappa   
• • ·Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis

    Pagina :1611-1619

    Jennifer A Crozier, Todd A Pezzi, Caitlin Hodge, Slavica Janeva, Beth-Ann Lesnikoski, Laila Samiian, Amanda Devereaux, William Hammond, Riccardo A Audisio, Christopher M Pezzi

    Riassunto Riassunto Mappa Mappa   
• • ·Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

    Pagina :1620-1629

    Thierry André, Jeffrey Meyerhardt, Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Ioannis Souglakos, Axel Grothey, Donna Niedzwiecki, Mark Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Dewi Vernerey, Jeffrey Meyers, Andrea Harkin, Valter Torri, Eiji Oki, Vassilis Georgoulias, Julien Taieb, Anthony Shields, Qian Shi

    Riassunto Riassunto Mappa Mappa   
• • ·Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

    Pagina :1630-1642

    Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Elizabeth A Punnoose, Wan-Jen Hong, Kevin J Freise, Xiaoqing Yang, Anjla Sood, Muhammad Jalaluddin, Jeremy A Ross, James E Ward, Paulo C Maciag, Philippe Moreau

    Riassunto Riassunto Mappa Mappa   
• • ·Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

    Pagina :1643-1652

    Carolina Porras, Sabrina H Tsang, Rolando Herrero, Diego Guillén, Teresa M Darragh, Mark H Stoler, Allan Hildesheim, Sarah Wagner, Joseph Boland, Douglas R Lowy, John T Schiller, Mark Schiffman, John Schussler, Mitchell H Gail, Wim Quint, Rebeca Ocampo, Jorge Morales, Ana C Rodríguez, Shangying Hu, Joshua N Sampson, Aimée R Kreimer, Costa Rica Vaccine Trial Group, Bernal Cortés, Paula González, Rolando Herrero, Silvia E Jiménez, Carolina Porras, Ana Cecilia Rodríguez, Allan Hildesheim, Aimée R Kreimer, Douglas R Lowy, Mark Schiffman, John T Schiller, Mark Sherman, Ligia A Pinto, Troy J Kemp, Mary K Sidawy, Wim Quint, Leen-Jan Van Doorn, Linda Struijk, Joel M Palefsky, Teresa M Darragh, Mark H Stoler

    Riassunto Riassunto Mappa Mappa   
• • ·Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

    Pagina :1653-1660

    Jin Won Youn, Soo-Young Hur, Jung Won Woo, Yong-Man Kim, Myong Cheol Lim, Sang Yoon Park, Sang Soo Seo, Jae Hong No, Byoung-Gie Kim, Jae-Kwan Lee, So Jin Shin, Kyungun Kim, Marya F Chaney, Yoon-Jeong Choi, You Suk Suh, Jong Sup Park, Young Chul Sung

    Riassunto Riassunto Mappa Mappa   
• • ·Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

    Pagina :1661-1672

    Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, John K Chan, Minal A Barve, Jonathan Oh, Devansu Tewari, Peter C Morris, Erin E Stevens, Justin N Bottsford-Miller, Min Tang, Phylicia Aaron, Laura Stanbery, Staci Horvath, Gladice Wallraven, Ernest Bognar, Luisa Manning, John Nemunaitis, David Shanahan, Brian M Slomovitz, Thomas J Herzog, Bradley J Monk, Robert L Coleman

    Riassunto Riassunto Mappa Mappa   
• • ·Essential oncology nursing care along the cancer continuum

    Pagina :e555

    Annie M Young, Andreas Charalambous, Ray I Owen, Bernard Njodzeka, Wendy H Oldenmenger, Mohammad R Alqudimat, Winnie K W So

    Riassunto Riassunto Mappa Mappa  
• • ·Oncology nursing workforce: challenges, solutions, and future strategies

    Pagina :e564

    Julia M Challinor, Mohammad R Alqudimat, Tamara O A Teixeira, Wendy H Oldenmenger

    Riassunto Riassunto Mappa Mappa  
• • ·Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions

    Pagina :e575

    Charles L Bennett, Martin W Schoen, Shamia Hoque, Bartlett J Witherspoon, David M Aboulafia, Catherine S Hwang, Paul Ray, Paul R Yarnold, Brian K Chen, Benjamin Schooley, Matthew A Taylor, Michael D Wyatt, William J Hrushesky, Y Tony Yang

    Riassunto Riassunto Mappa Mappa  
• • ·Spontaneous pneumothorax secondary to an endometrial stromal sarcoma

    Pagina :e589

    Giselle A Suero-Abreu, Rahim H Wooley, Aldo Barajas-Ochoa, Constantinos Lovoulos, Keith P Guevarra